# 輝瑞股價於週一發稿時下跌1.3%，報25.70美元。

*biotech · news · 2026-06-08 · Benzinga*

## Key points

- 輝瑞的berobenatide在第二期2b試驗中，32週非安慰劑調整後體重減輕15.9%。
- 輝瑞於本次更新中首次公布berobenatide最高每週劑量的臨床結果。
- berobenatide的關鍵第三期臨床試驗現正招募肥胖症治療參與者。
- 輝瑞計劃於2026年針對多種共病進行十項額外的berobenatide第三期臨床試驗。
- HYMPAVZI的FDA適應症現已包含6至11歲的兒童B型血友病患者。

Pfizer Berobenatide Update On Saturday, the company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants. The pivotal Phase 3 study is currently open for enrollment, which may further bolster Pfizer’s position in the obesity treatment market. Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials. The first clinical experience with the top weekly dose for berobenatide is were presented for the first time. Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide. Phase 3 Program Expands FDA Expands HYMPAVZI Indication HYMPAVZI is the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B aged 6 to 11 years. PFE Stock Price Activity: Pfizer shares were down 1.3% at $25.70 at the time of publication on Monday, according to Benzinga Pro data. Photo: Molly Woodward / Shutterstock

**Companies:** Pfizer
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/06/53069479/pfizers-obesity-drug-shows-16-weight-loss-in-phase-2b-study)

---

Canonical: https://newsio.io/zh-TW/n/b9f55409-6dbb-48cf-bfcc-0eb14ccd9cba/1-325-70202610berobenatide
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works